Dr. Steven Wolf, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 247
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Albany Medical College of Union University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 183592
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Westchester Medical Center Valhalla, NY
Medical groups
- Boston Children's Health Physicians LLP (79 clinicians)
- Premier Healthcare Inc (58 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 247
- Services billed
- 654
- Patients’ average age
- 48
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 363 | 230 |
| Measurement of brain wave activity (eeg), 41-60 minutes | 72 | 65 |
| Measurement of brain wave activity (eeg), continuous | 44 | 41 |
| Measurement of brain wave activity (eeg), 12-26 hours | 44 | 41 |
| Measurement of brain wave activity (eeg), 12-26 hours with health care professional review and report | 42 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 26 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 24 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
| Insertion of needle into vein for collection of blood sample | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levetiracetam Other prescribers in New York, NY | 507 |
| Divalproex Sodium Other prescribers in New York, NY | 295 |
| Lacosamide Other prescribers in New York, NY | 183 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in New York, NY | 158 |
| Carbamazepine Er (carbamazepine) Other prescribers in New York, NY | 149 |
| Lamotrigine Other prescribers in New York, NY | 134 |
| Topiramate Other prescribers in New York, NY | 130 |
| Donepezil Hcl Other prescribers in New York, NY | 106 |
| Oxcarbazepine Other prescribers in New York, NY | 105 |
| Clobazam | 97 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 156 payments worth $48,371 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $13,829 |
|---|---|
| UCB Biosciences Inc. | $8,500 |
| Neurelis, Inc. | $8,147 |
| UCB, Inc. | $7,671 |
| Monteris Medical Corporation | $4,498 |
| Otter Pharmaceuticals, LLC | $2,778 |
| Livanova USA, Inc. | $1,440 |
| Sk Life Science, Inc. | $487 |
| Compensation for services other than consulting (speaking, faculty) | $34,985 |
|---|---|
| Consulting Fee | $5,926 |
| Food and Beverage | $4,448 |
| Travel and Lodging | $3,011 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $6,785 |
| UCB Biosciences Inc. Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $5,400 |
| UCB, Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $4,000 |
| Monteris Medical Corporation Jun 30, 2025 | Consulting Fee Neuroblate | $3,250 |
| UCB Biosciences Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $3,100 |
| Otter Pharmaceuticals, LLC Apr 23, 2025 | Consulting Fee SYMPAZAN · Neurology | $2,676 |
| Neurelis, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $2,376 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
| Jazz Pharmaceuticals Inc. Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
All 31 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Neurelis, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $2,376 |
| Neurelis, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $1,485 |
| UCB Biosciences Inc. Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $5,400 |
| Jazz Pharmaceuticals Inc. Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
| Livanova USA, Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) VNS THERAPY SENTIVA MODEL 1000 GENERATOR · Neurology | $480 |
| Neurelis, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $1,485 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
| UCB Biosciences Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $3,100 |
| Neurelis, Inc. Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $1,152 |
| UCB, Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $4,000 |
| Neurelis, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) VALTOCO · EPILEPSY | $1,152 |
| Livanova USA, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) VNS THERAPY SENTIVA MODEL 1000 GENERATOR · Neurology | $960 |
| UCB, Inc. Aug 11, 2025 | Travel and Lodging Fintepla · Neurology · travel to Albany, NY · in-kind | $1,068 |
| Jazz Pharmaceuticals Inc. Jul 30, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Rosemont, IL · in-kind | $165 |
| UCB, Inc. Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $1,300 |
| Jazz Pharmaceuticals Inc. Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $6,785 |
| UCB, Inc. Jul 22, 2025 | Travel and Lodging Fintepla · Neurology · travel to Albany, NY · in-kind | $15.00 |
| Jazz Pharmaceuticals Inc. Jul 18, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Chicago, IL · in-kind | $400 |
| Jazz Pharmaceuticals Inc. Jul 18, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Chicago, IL · in-kind | $235 |
| Monteris Medical Corporation Jun 30, 2025 | Consulting Fee Neuroblate | $3,250 |
| Monteris Medical Corporation Jun 30, 2025 | Travel and Lodging Neuroblate · travel to Minneapolis, MN · in-kind | $84.50 |
| Monteris Medical Corporation Jun 30, 2025 | Travel and Lodging Neuroblate · travel to Minneapolis, MN · in-kind | $70.11 |
| Monteris Medical Corporation Jun 30, 2025 | Travel and Lodging Neuroblate · travel to Minneapolis, MN · in-kind | $47.23 |
| Monteris Medical Corporation Jun 17, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $84.50 |
| Monteris Medical Corporation Jun 17, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $41.10 |
| Monteris Medical Corporation Jun 16, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $358 |
| Monteris Medical Corporation Jun 16, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $325 |
| Monteris Medical Corporation Jun 16, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $70.11 |
| Monteris Medical Corporation Jun 16, 2025 | Travel and Lodging Neuroblate · travel to Montreal, QC, Canada · in-kind | $47.23 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) EPIDIOLEX · NEUROLOGY | $1,770 |
| Otter Pharmaceuticals, LLC Apr 23, 2025 | Consulting Fee SYMPAZAN · Neurology | $2,676 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $115,307 in research payments for these studies, mostly to the institutions running them.
- An open-label, single-dose, pharmacokinetics study of valtoco with open-label safety period in pediatric subjects with epilepsy
Neurelis, Inc. - A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
UCB SA · Recruiting · NCT04715646 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
UCB SA · Terminated · NCT04519645 - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc. - Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Sk Life Science, Inc. · Completed · NCT05067634
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.